Mersana Therapeutics Inc

MRSN03 Dec 2024
Healthcare
$2.34
+0.00 (+0.44%)
Lowest Today
$2.24
Highest Today
$2.35
Today’s Open
$2.34
Prev. Close
$2.28
52 Week High
$6.28
52 Week Low
$1.22
To Invest in Mersana Therapeutics Inc

Mersana Therapeutics Inc

Healthcare
MRSN03 Dec 2024
+0.00 (+0.44%)
1M
3M
6M
1Y
5Y
Low
$2.24
Day’s Range
High
$2.35
2.24
52 Week Low
$1.22
52-Week Range
52 Week High
$6.28
1.22
1 Day
-
1 Week
+14.25%
1 month return
+22.19%
3 month return
+44.62%
6 month return
-5.18%
1 Year return
+38.48%
3 Years return
-66.04%
5 Years return
-42.73%
10 Years return
-
Institutional Holdings
EcoR1 Capital, LLC
15.76
Nextech Invest AG
9.82
VR Adviser, LLC
9.22
Bain Capital Life Sciences Investors, LLC
7.05
BlackRock Inc
6.82
Vanguard Group Inc
5.84
Morgan Stanley - Brokerage Accounts
3.7

Market Status

Fundamentals
Market Cap
270.54 mln
PB Ratio
257.9
PE Ratio
0
Enterprise Value
146.87 mln
Total Assets
226.06 mln
Volume

Company Financials

Fund house & investment objective

Company Information
Mersana Therapeutics, Inc., a clinical stage biopharmaceutical company, develops antibody drug conjugates (ADC) for cancer patients with unmet needs. The company develops XMT-1660, a B7-H4-targeted Dolasynthen ADC candidate; and XMT-2056, an immunosynthen ADC. It has research and development collaborations with Janssen Biotech, Inc., Ares Trading S.A., Merck KGaA, and Asana BioSciences, LLC for the development of ADC product candidates. The company was formerly known as Nanopharma Corp. and changed its name to Mersana Therapeutics, Inc. in November 2005. Mersana Therapeutics, Inc. was incorporated in 2001 and is headquartered in Cambridge, Massachusetts.
Organisation
Mersana Therapeutics Inc
Employees
123
Industry
Biotechnology
CEO
Dr. Martin H. Huber M.D.
Trading and brokerage services provided by
Technology Services provided by Motilal Oswal Financial Services:

Take your next step

Click here to see your activities